The Danish laboratory Novo Nordisk in Algeria has just reacted to the serious accusations launched last Wednesday by the Minister of Pharmaceutical Industry Lotfi Benbahmed.
In a clarification received this Friday, April 29, by our editorial staff, Novo Nordisk Algeria responded to Benbahmed’s accusations, providing details on the insulin production file.
Calling the minister’s remarks allegations, Novo Nordisk strongly contested Benbahmed’s accusations. “We strongly contest all of these allegations,” the Danish laboratory said in the press release.
“Novo Nordisk has been present in Algeria for 86 years and continues to develop its investments, particularly industrial, with two production sites. In this regard, Algeria is one of the few countries in the world to benefit from such a transfer of production from our group,” added the same source.
“Novo Nordisk Algeria is at the service of patients by providing them and healthcare professionals with innovative therapeutic solutions for which medical information is shared reliably and documented for their proper use”, recalled the Danish laboratory.
“In this context, Novo Nordisk Algérie does not allow itself any compromise on the quality, use and ethical promotion of its products and shows particular vigilance in respecting these
commitments in accordance with the legislation and regulations in force”, concluded the same source.
The serious accusations of Benbahmed
In a statement given to Santé News on Wednesday, Minister Benbahmed accused the Novo Nordisk laboratory of wanting to create tensions within the Algerian market to exert some lobbying and pressure on the government.
“They go to doctors in order to scare the sick. They make them believe that there will be disruptions in the market and that they will no longer be able to find their medicines,” Benbahmed said.
” Why ? Because we are the first customers of the laboratory in Africa, even in the entire Mena region, to have lowered their prices. We lowered them according to those of Tunisia, because before they were higher. That’s what prompted them to do some lobbying and pressure,” he explained.